Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.

The weight-loss drug market is projected to approach $100 billion by the end of the decade. Viking has a candidate in two formulations undergoing Phase 3 studies, positioning it in the growing market; the article provides no trial results or company-specific financial figures.